Hydralazine and magnesium valproate as epigenetic treatment for myelodysplastic syndrome. Preliminary results of a phase-II trial

@article{Candelaria2010HydralazineAM,
  title={Hydralazine and magnesium valproate as epigenetic treatment for myelodysplastic syndrome. Preliminary results of a phase-II trial},
  author={M. Candelaria and Aquileo Herrera and J. Labardini and A. Gonz{\'a}lez-Fierro and C. Trejo-Becerril and L. Taja-Chayeb and E. P{\'e}rez-C{\'a}rdenas and E. Cruz-Hern{\'a}ndez and Daymi Arias-Bofill and S. Vidal and E. Cervera and A. Duenas-Gonzalez},
  journal={Annals of Hematology},
  year={2010},
  volume={90},
  pages={379-387}
}
  • M. Candelaria, Aquileo Herrera, +9 authors A. Duenas-Gonzalez
  • Published 2010
  • Medicine
  • Annals of Hematology
  • Decitabine and azacitidine, two DNA methyltransferase (DNMT) inhibitors, are the current standard of treatment for myelodysplastic syndrome (MDS). Histone deacetylase (HDAC) inhibitors are also being tested against MDS. Both drug classes synergize in their gene reactivating and anticancer activities. The combination of hydralazine and valproate (Transkrip®), a DNMT and HDAC inhibitor, respectively), has been developed as epigenetic therapy under the drug repositioning concept. To evaluate the… CONTINUE READING
    51 Citations

    Paper Mentions

    Interventional Clinical Trial
    The purpose of this study is to determine the efficacy and safety the combination of TRANSKRIP ® vs placebo plus Carboplatin/Paclitaxel as first line treatment in patients with… Expand
    ConditionsCervical Cancer
    InterventionDrug
    Pharmacokinetics of hydralazine, an antihypertensive and DNA-demethylating agent, using controlled-release formulations designed for use in dosing schedules based on the acetylator phenotype.
    • 14
    Epigenetic regulation in myelodysplastic syndromes: implications for therapy
    • 20

    References

    SHOWING 1-10 OF 42 REFERENCES
    Valproic Acid at Therapeutic Plasma Levels May Increase 5-Azacytidine Efficacy in Higher Risk Myelodysplastic Syndromes
    • 94
    • PDF
    Treatment of poor-risk myelodysplastic syndromes and acute myeloid leukemia with a combination of 5-azacytidine and valproic acid
    • 48
    • PDF
    Demethylating agents in myeloid malignancies
    • 104
    Current status of epigenetic treatment in myelodysplastic syndromes
    • 92